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INTRODUCTION 
 
           Diabetes is a major non communicable disease worldwide. Recent 
data indicate that around 390 million people across the globe have 
diabetes and this number is expected to rise up to 595 million over the 
next twenty years. In India there are about 65 million diabetics.  
 
           Diabetes is associated with both micro vascular complications     
(retinopathy, neuropathy, nephropathy) as well as macro vascular 
complications like cerebro vascular diseases, peripheral arterial diseases 
and cardio vascular diseases. The risk of chronic complications increase 
with the duration of diabetes. Several theories have been proposed for the 
pathogenesis of such chronic complications including – 
 
1) Advanced glycosylation end products 
2) Sorbitol pathway 
3) Protein Kinase C pathway 
4) Hexosamine pathway 
5) Oxidative stress 
 
          Recent studies have shown that the above mentioned advanced 
glycation end products elicit a chronic low grade inflammation which 
correlates with the degree of organ damage.  
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Hence our study is aimed at assessing the levels of two of the 
markers of inflammation (acute phase reactants ) namely serum CRP and 
serum fibrinogen in patients with long standing type 2 diabetes and 
determining whether they correlate with the degree of albuminuria ( an 
indicator of the degree of nephropathy ). 
 
           About 100 patients with type 2 diabetes mellitus are subjected to 
clinical assessment including body mass index, waist hip ratio, blood 
pressure as well as laboratory testing for fasting plasma glucose, serum 
CRP, serum fibrinogen , 24 hours urinary albumin , serum creatinine . 
The levels of the above mentioned acute phase reactants are compared 
with the levels of albuminuria  and assessed for the presence of  any 
significant correlation 
 
  
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
PRIMARY OBJECTIVES  
 
To study the corelation between levels of acute phase reactants  
(serum CRP, serum fibrinogen) and severity of albuminuria in patients 
admitted with type 2 diabetes mellitus. 
 
 
SECONDARY OBJECTIVES 
To assess the clinical and laboratory profile (BMI, WHR, BP, RFT, 
Fasting glucose) of diabetic patients with varying levels of Albuminuria. 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
Diabetes is a chronic metabolic disorder which may be defined as 
the presence of hyperglycaemia due to defective secretion of insulin, 
defective action of insulin or a combination of both. The chronically 
elevated glucose levels may result in long term microvascular 
complications like neuropathy, nephropathy and retinopathy as well as 
macro vascular complications like cardio vascular, cerebrovascular and 
peripheral vascular diseases. Pre diabetes refers to states of impaired 
glucose tolerance, impaired fasting glucose or HBA1 C levels of  
5.7 to 6.4. 
 
DIABETES – HISTORICAL ASPECTS 
An ancient Egyptian manuscript namely the Ebers Papyrus, written 
in 1500 BC mentions a disease characterised by “too great emptying of 
the urine ”, probably referring to diabetes. Ancient Indian physicians also 
recognised that ants are attracted to the urine of these patients and hence 
termed this condition “madhumeha” or “honey urine”. In 230 BC, 
Apollonius of Memphis referred to this disease as Diabetes which means 
“to pass through”. The term mellitus which refers to honey was added 
later on to distinguish this disease from another disease characterised by 
polyuria namely diabetes insipidus.   
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 In the fifth century AD, Indian physicians Sushrutha and Charakha 
had described thin individuals who developed diabetes at an earlier age 
and obese individuals who developed a milder form of the condition at a 
later age group, thus making them probably the first ever to distinguish 
between the two types of diabetes. In the tenth century AD, Avicenna 
also known as Ibn Sina described the complications of this disease 
including digital gangrene and sexual dysfunction.  
 
In the year 1776, Mathew Dobson, an English physiologist proved 
that the urine of the diabetic patients had elevated levels of sugar. A 
quantitative test for detecting glucose in the urine was developed by Von 
Fehling in the year 1848. Frederick Banting and his student Charles Best 
purified and extracted insulin in the year 1921 for which the Nobel Prize 
was awarded. Hans Christian discovered that the addition of hagedorn 
can prolong the life of insulin. 
 
With improvement of the purification and extraction techniques, 
longer acting insulins namely the protamine zinc insulin, neutral 
protamine hagedorn insulin and the lente insulins were produced. 
Frederick Sanger discovered the amino acid sequence of insulin which 
facilitated the subsequent artificial synthesis of insulin 
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The following chart depicts the timeline of insulin discovery. Paul 
Langerhans first discovered that there are specialised cells within the 
pancreas with endocrine function and these subsequently came to be 
called the islets of Langerhans.  
 
 
In the year 1918, C.K.Watanabe, while investigating the properties 
of guan iodine noted that it produced hypoglycaemia in rabbits. Hence 
derivatives of guanidine namely monoguanides and biguanides were 
developed as hypoglycaemic agents. Phenformin, a biguanides was the 
first effective oral hypoglycaemic agent. In the nineteen forties, Celestino 
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Ruiz, L.L.Silva of Argentina and M.J.Janbon of France independently 
observed that certain sulphonamide derivatives (which were then used as 
antibiotics) had hypoglycaemic properties. Subsequently potent sulfonyl 
urea drugs have been developed to control the sugar levels in diabetic 
patients. 
 
DIABETES PREVALENCE 
 
As per the World Health Organisation (WHO), there has been an 
increase in the number of people living with diabetes from 108 million in 
1980 to 422 million in 2014. The overall prevalence of diabetes in people 
above 18 years of age has increased from 4.7 % in 1980 to 8.5 % in 2014. 
The developing countries have been showing a significant increase in the 
incidence of diabetes, probably due to their changing lifestyle patterns 
which subsequently lead to an increase in the proportion of overweight 
population. According to the data recorded in 2012, almost 1.5 million 
deaths globally were directly attributable to diabetes. 
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WORLD MAP SHOWING THE PERCENTAGE OF TYPE 2 
DIABETICS AMONG THE GENERAL POPULATION 
 
When this map was compared to the map depicting the obesity 
distribution across the global population , both were found to correlate 
with one another , indicating that obesity and type 2 diabetes are causally 
linked. 
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ECONOMIC IMPACT OF DIABETES MELLITUS 
 
Diabetes produces a huge economic strain on the healthcare 
establishment of a country. The proportion of healthcare funds allotted to 
diabetes at the global level constituted about 11.6 %. But this expenditure 
on the diabetic population is not evenly distributed across age, gender and 
country.  
 
Such a large economic burden due to diabetes, especially in a 
country like India is borne by the individual and not the state. Due to the 
poorly organized system of medical care, inadequate insurance coverage 
and uneven distribution of medical services, the people with diabetes 
often have to spend almost a quarter of their total income on the 
management of their  health. Diabetic complications can result in 
disability, loss of life and reduced quality of life.  
 
  Several analyses have been performed in the western countries to 
assess the economic impact of diabetes. These have shown that there is 
direct and indirect cost incurred by the diabetic population.  
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The direct costs are as follows: 
1. Physician service cost  
2. Hospital service cost 
3. Costs related to medications  
4. Laboratory services costs 
 
The indirect costs are as follows : 
1. Loss of productivity  
2. Short term morbidity  
3. Permanent disability 
4. Premature mortality 
 
Diabetes is growing at an alarming pace in  India. Statistics 
indicate that about 65.1 million people live with diabetes (compared to 
50.9 million in 2010).  
By 2030, probably India will have about 100 million diabetics. 
This striking increase in the incidence of diabetes is perhaps  related to 
the rapid urbanization and westernisation of lifestyle. Deaths due to 
diabetes is also quite high (about 4 million per year).  
 
Therefore, in a developing country like India which has a very 
large diabetic population, early diabetes detection and prompt initiation of 
treatment in the outpatient setting is a must. 
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The following picture shows that India has one of largest diabetic 
populations in the world and yet it spends a disproportionate amount of 
funds for the their healthcare. 
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RISK FACTORS FOR DIABETES 
 
The risk factors for type 2 diabetes may be classified as modifiable 
and non modifiable factors. 
 
 
 
The risk factors for type 1 diabetes include genetic factors (positive 
family history), pancreatic diseases, infections and auto immunity. 
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CLASSIFICATION OF DIABETES 
 
 
The World Health Organisation in collaboration with the expert 
committee of the American Diabetes Association formulated a widely 
acceptable classification of the types of diabetes. The previous  
terminologies namely insulin dependent diabetes and non insulin 
dependent diabetes were noted to be confusing and misleading and hence 
discarded.  
As per this classification the major types of diabetes are type 1 
diabetes, type 2 diabetes, gestational diabetes mellitus and other specific 
types. The distinction between type 1 and type 2 diabetes gains 
significance due to the fact that the management principles are different 
for both of them. These two types may be differentiated on the basis of 
clinical signs of insulin resistance, markers of autoimmunity  
(anti glutamic acid decarboxylase antibody and anti islet cell antibody)  
and C peptide levels. The type 1 diabetes also includes the category -
LADA (latent autoimmune diabetes in adults) which refers to the patients 
with apparent type 2 diabetes who are however noted to have 
autoimmune destruction of beta cells of pancreas. 
A comprehensive etiology based classification of diabetes is shown 
in the following table. 
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ETIOLOGICAL CLASSIFICATION OF DIABETES 
 
 
 
GESTATIONAL DIABETES 
Pregnancy can cause several changes in the maternal carbohydrate 
metabolic pathways. The placental hormones have an anti insulin effect 
and pregnancy as such is a state of insulin resistance. There has to be a 
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compensatory increase in the secretion of insulin to counter these effects. 
When this compensation is inadequate, gestational diabetes develops.  
Gestational diabetes is diagnosed based on the ADA (75 or 100 gm 
OGTT) or  (75 gm OGTT ) criteria. 
 
OTHER TYPES OF DIABETES 
(A) MONOGENIC DIABETES 
Monogenic diabetes refers to a disease state characterized by single 
gene mutations. It usually constitutes about 1% of the diabetic population. 
The genetic mutations may be autosomal dominant or recessive. The 
monogenic diabetes categorisation is important because of  the  fact that it 
may mimic type 1 or type 2 diabetes. 
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A small portion of suspected type 2 diabetic population have later 
been  found  to have a late onset form of autoimmune mediated diabetes 
while some others have been found to have MODY and mitochondrial 
diabetes. 
(B) DISEASES OF EXOCRINE PANCREAS CAUSING DIABETES 
1. Pancreatectomy 
2. Acute pancreatitis 
3. Chronic pancreatitis 
4. Hemochromatosis 
5. Carcinoma 
6. Cystic fibrosis 
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(C) DRUG INDUCED DIABETES 
There are several drugs which can interfere with the glucose 
homeostasis and thereby result in a state of hyperglycemia. The most 
important of these are glucocorticoids, oral contraceptive pills,  hormone 
replacement therapy, thiazide diuretics, non selective beta blockers,  
streptozotocin,  pentamidine,  cyclosporine,  diazoxide, tacrolimus etc. 
The list of drugs causing diabetes and the mechanisms for the same 
are explained in the following picture. 
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(D) DISEASES OF ENDOCRINE PANCREAS CAUSING 
DIABETES 
1. Glucagonoma 
2. Somatostatinoma  
3. Gastrinoma 
4. VIPoma 
5. Carcinoid syndrome 
 
(D) ENDOCRINOPATHIES CAUSING DIABETES 
1. Acromegaly 
2. Cushings syndrome  
3. Pheochromocytoma 
4. Hyperthyroidism 
5. Hyperparathyroidism 
6. Hyper aldosteronism 
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GLUCOSE HOMEOSTASIS 
Adequate blood glucose level is essential, because the brain and 
RBCs utilise glucose for their function. 
Maintenance of blood glucose level is under the control of several 
mechanisms. The body maintains glucose level with the help of two 
major hormones  
1.INSULIN 
2.GLUCAGON 
 
INSULIN  
Insulin is a hormone that is produced in the islets of langerhans in 
the pancreas. These islets contain alpha cells, beta cells, delta cells and 
PP cells. The beta cells are the source of insulin, while the alpha cells 
secrete glucagon. Delta cells and the PP cells synthesise somatostatin & 
pancreatic polypeptide respectively.  
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INSULIN SYNTHESIS 
Each of the islets of Langerhans contain about 2000 beta cells. The 
beta cells are particularly concentrated near the tail end of the pancreas. 
The human insulin gene is present in the 11p13 region of the 
chromosome.  Initial polypeptide synthesized by the beta cell is known as 
the preproinsulin. This is broken down to form the pro insulin. The 
proinsulin is packed into vesicles which are transported in the form of 
granules to the surface. The pro insulin consists of insulin chain and C 
peptide. Therefore insulin and C peptide are released in equimolar 
concentrations. The beta cells have a readily available pool of  pre formed 
insulin that can be immediately released in response to an elevation in the 
blood glucose levels.   
The islets are stimulated by the parasympathetic to secrete insulin. 
The beta cells can detect even minute changes in the blood glucose levels 
and respond by secreting insulin.  The insulin thus secreted goes and 
binds to the insulin receptor which is a glycoprotein composed of alpha 
and  beta subunits. After the binding of insulin to its receptor , tyrosine 
kinase enzyme is activated producing a cascade reaction , finally 
terminating in the  transcription of selective proteins. 
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The following picture shows the insulin synthesis from the single peptide. 
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INSULIN SECRETION 
Insulin is secreted in response to a parenteral glucose load in a 
biphasic manner.  
First phase : 
There is an initial surge in insulin levels following a glucose load 
which is known as the first phase of insulin secretion. This occurs  
approximately  2 to 3 minutes after the elevation of glucose levels. This 
returns to baseline within 7 to 10 minutes. The first phase is release of 
insulin is related to insulin secretory granules, which is located near to the 
beta cell membrane  
 
Second phase: 
 Second phase is characterised by a slow rise in the levels of 
insulin. This phase insulin release is related to production of new insulin. 
In between these peaks, there is a basal level of insulin secretion by the 
islet cells. The severity of diabetes is inversely proportional to the peak of 
this second phase of insulin secretion.  
Insulin is secreted in a continuous basal pattern as well as post 
prandial pulses.  
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The following picture indicates the secretory pattern of insulin. 
 
 
The first phase and second phase release of insulin are  altered in 
diabetics. The maximal secretary capacity of the beta cells is found to to 
be reduced.  The amplitude of the secretory pulses is also reduced. The 
proportion of preproinsulin to insulin is noted to be high. 
Insulin secretion throughout the day is approximately about 40 
units. Secretion of insulin was found to be pulsatile.  
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This pulsatile secretion comprises of  two pulses :- 
 short (rapid) pulse and 
long (ultradian) pulse 
This ultradian pulsation is amplified in post prandial state. These  
pulses are responsible for the oscillatory activity of beta cells. This 
oscillatory activity is an  important marker for early beta cell dysfunction 
in type 2 diabetes mellitus. 
MECHANISM OF ACTION OF INSULIN 
Glucose transport across plasma membrane is mainly mediated by 
glucose transport proteins  (GLUT). Now 13 members of the  GLUT 
family have been  identified. Among these,  GLUT- 1 and GLUT- 4 are 
the two main isoforms  mediating  glucose transport in cells .  
GLUT-1 is seen on the  cell surface and  it facilitates glucose 
diffusion across plasma membrane into cytosol. GLUT-4 mediates insulin 
stimulated glucose transport into the tissues like muscles ( skeletal, 
cardiac )  and adipose tissue. 
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In muscle insulin increases glucose entry, glycogen synthesis, 
increased amino acid uptake  and  protein synthesis. In liver it  increases 
lipid synthesis and decreases glucose output. This hepatic glucose output  
is mainly responsible for the  raised blood glucose level in a  fasting state. 
The peripheral utilisation of  glucose is determines the  post prandial 
plasma glucose levels. Insulin acts as  an anabolic as well as a catabolic 
hormone. In liver and kidney,  insulin is metabolised by the enzyme 
insulinase. 
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PATHOGENESIS OF DIABETES 
Earlier,  type 2 diabetes was considered to be a disease of elderly 
individuals. But in recent times it has been noted to occur in adolescents 
and young children as well. Type 2 diabetes mellitus is caused by 
environmental as well as genetic factors.  
The genetic factors contribute to  reduced functioning of beta 
cell while the environmental factors (namely  sedentary lifestyle, obesity, 
elevated carbohydrate intake  and lipid toxicity)  contribute to the 
resistance to the action of insulin. At the time of diagnosis of type 2 
diabetes itself, the beta cell function is likely to be only about 50 
percentage of the normal 
The theories postulated for the  pathogenesis of type 2 diabetes mellitus 
are as follows : 
1. Beta cell dysfunction (impaired insulin secretion) 
2. Insulin  resistance 
3. Increase hepatic glucose output 
4. Abnormal fat metabolism 
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BETA CELL DYSFUNCTION 
 
Beta cells are situated in the islets of Langerhans in  the pancreas. 
Main role of the beta cells is the  synthesis of insulin. In type 2 diabetes 
mellitus, there is failure or alteration in the beta cell function. The 
contributory factors are glucotoxicity, lipotoxicity, ER stress, 
mitochondrial dysfunction, oxidative stress, islet inflammation etc. 
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There are several abnormalities of insulin secretion noted in type 2 
diabetes mellitus. They are enlisted below 
1. Reduced glucose sensing  
2. Altered response of islet cells to the fluctuations of blood 
glucose levels 
3. Inadequate first phase insulin secretion 
4. Poor early insulin secretion in response to oral glucose 
challenge 
5. Abnormalities in the rapid oscillatory phases of insulin 
secretion  
6. Diminished effect of gastrointestinal hormones in facilitating 
glucose mediated insulin production ( incretin effect)  
7. Insufficient secretion of insulin -- such that the insulin levels do 
not  correspond to the severity of hyperglycemia 
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INSULIN RESISTANCE 
Insulin resistance refers to a state of sub optimal functional 
response to a specified concentration of insulin. There are various 
methods to quantitatively determine the insulin resistance. In type  
2 diabetes, there is resistance to the action of insulin and also an absolute 
insulin deficiency. Often the metabolic syndrome precedes type  
2 diabetes. Metabolic syndrome is characterized by the presence of 
insulin resistance, elevated blood pressure, altered lipid levels and 
visceral obesity.  The criteria for the diagnosis of the metabolic syndrome 
is as follows  
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For a certain period, the pancreatic islet cells compensate for the 
resistance to insulin action by increasing the quantity of insulin 
secreted but after a certain time interval there is a gradual decline in the 
functioning of the islet cells. This is followed by progressive 
hyperglycemia. 
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In these insulin resistance states, there is a reduced ability of 
insulin to inhibit the glucose production in the liver, thereby resulting in  
hyperglycemia. In the adipose tissue there is altered production of 
adiponectin (which normally facilitates insulin action) and reduced ability 
of insulin to inhibit lipolysis, as a result of which the fatty acid levels are 
elevated. Adiponectin deficiency is also considered to be contributory to 
the development of fatty liver in diabetic patients. 
The insulin resistance in the hepatic tissue causes elevated levels of 
very low density lipoprotein and triglycerides but there is a decrease in 
the levels of high-density lipoprotein because cholesterol esters are 
removed from it by the CETP protein. 
In the skeletal muscles the insulin mediated uptake of glucose is 
diminished glycogen synthesis is also reduced. 
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The following picture depicts the effects of insulin deficiency and 
insulin resistance on the liver, adipose tissue and the skeletal muscles. 
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COMPLICATIONS OF DIABETES 
The complications of diabetes are categorised as acute and chronic 
complications.  
1. ACUTE COMPLICATIONS 
1. Diabetic keto acidosis 
2. Hyper osmolar hyperglycemic state 
3. Hypoglycemia ( treatment related ) 
 
2.  CHRONIC COMPLICATIONS  
The major complications of diabetes may be categorized as  
micro vascular and macro vascular complications.  
 
1. The micro vascular complications include diabetic retinopathy, 
diabetic  nephropathy and peripheral neuropathy.  
2. The macro vascular complications are cardio vascular diseases , 
cerebro vascular diseases and peripheral vascular diseases. 
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ACUTE COMPLICATION: 
These acute diabetic complications are considered to be medical 
emergencies. They are  Diabetic  Keto Acidosis (DKA),  Hyper osmolar 
Hyperglycemic Syndrome (HHS) and Hypoglycemia. 
DIABETIC KETOACIDOSIS 
Diabetic ketoacidosis occurs due to a state of  insulin deficiency 
and excess counter regulatory hormones. The deficiency of insulin leads 
to   poor peripheral uptake of glucose. 
The altered insulin glucagon ratio facilitates hepatic 
gluconeogenesis. The excess counter regulatory hormones especially 
glucagon causes activation of beta oxidation of fatty acids. This produces 
acetyl co A via the  ketogenic pathway. Products of this pathway include 
the  ketone bodies which produce ketosis and acidosis. The ketone bodies 
are acetone, beta hydroxyl butyrate and aceto acetate. The ensuing 
acidosis is detrimental to the tissues of the heart and central nervous 
system. DKA can result in osmotic diuresis induced severe dehydration 
also. 
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Dka  can be associated with hyponatremia due to the osmotic  
diuretic effect of glucose as well as the  excretion of cations along with 
the negatively charged ketone bodies. Hypokalemia  can occur due to the 
osmotic diuretic effect as well as gastrointestinal losses associated with 
vomiting. 
HHS  
Hyperosmolar hyperglycemic syndrome,  previously known as the 
hyperosmolar nonketotic syndrome occurs due to the elevated glucose 
levels and  volume depletion. It is secondary to osmotic diuresis and 
hyper osmolality. It has a significant mortalityrate.  It is often precipitated 
by infection, alcohol, myocardial infarction and drugs like diuretics. HHS 
can lead onto coma, seizures and renal failure. It is treated with half 
normal saline, insulin, electrolyte repletion and treatment of the 
underlying cause. 
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The following picture shows the pathophysiology of diabetic keto 
acidosis and hyper osmolar hyperglycaemic states 
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HYPOGLYCEMIA 
Hypoglycemia is often secondary to drugs used in management of 
diabetes. Hypoglycaemia refers to a state of low  blood glucose level < 50 
mg  
Clinical symptoms of hypoglycemia 
 
 
Short duration of low blood sugar level can manifest as giddiness, 
undue sweating, seizures etc.  It may be treated with parenteral 
administration of glucose solution.  Prolonged period leads to tissue 
damage and brain death. 
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CHRONIC COMPLICATIONS 
 
The major chronic complications in diabetes mellitus are caused by 
the persistent elevated glucose levels as proved by that DCCT  Trial. 
States of continuous hyperglycemia in association with  hypertension, 
dyslipidemia, smoking , alcoholism , dietary habits, and environment 
factors can  result in structural alterations which lead on to organ damage. 
The chronic complications of diabetes are principally caused by the  
 Vascular changes and the 
 Metabolic changes associated with this disease. 
The vascular changes in diabetes are as follows : 
1. Diminished contractility of the vessels   
2. Thickening of the basement membrane 
3. Hypercoagulability due to alterations in levels of clotting factor 7  
and von willebrand factor           
4. Excess  neo vascularisation  
Chronic hyperglycemia may be associated with endothelial 
dysfunction which is secondary to imbalance between the factors that 
cause contractility and those that cause vasodilatation. 
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5. Serum fibrinogen levels are found to be elevated in diabetes and 
this    may contribute to a procoagulant state.  Also co-morbid 
condition like hypertension have  been shown to accelerate the 
severity of chronic complications of diabetes; this was proven in 
the DCCT AND UKPDS trials.  For every 10 mm Hg reduction of 
the systolic blood pressure, there is a 12%  reduction in the risk of 
myocardial infarction. 
The metabolic pathways and involved in  diabetic complications are as 
follows  
(a)  Abnormalities in the aldose reductase pathway                        
(b)  Diacylglycerol protein kinase pathway  
(c) Activation formation of Advanced glycation end products 
(AGE) 
(d)  Synthesis of reactive oxygen species 
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MICRO VASCULAR COMPLICATIONS 
DIABETIC RETINOPATHY 
Some of the earliest changes noted in the retina of diabetic patients are 
1. Micro aneurysms 
2. Dot and blot  haemorrhage 
3. Chronic hypoxia can result in excess vascular tissue 
proliferation known as neovascularisation. But the newly 
formed blood vessels are highly permeable  and prone for 
damage – leading to retinal and vitreous haemorrhages 
DIABETIC NEUROPATHY 
Diabetic neuropathy is due to the  effect of  advanced  glycation 
end products and othet toxic compounds  on the peripheral nerves.  It can 
also be due to athero sclerosis of  the vasa nervosum which supply the 
nerves. 
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DIABETIC NEPHROPATHY 
One of the major complications of diabetes is diabetic 
nephropathy. It is characterised by the excretion of albumin in the urine 
in the early stages while in the later stages there is a progressive decline 
in the glomerular filtration rate , elevated creatinine and hypertension. 
The usual time period taken for the  development of diabetic nephropathy 
from the onset of diabetes is around 15 to 20 years. Several factors 
contribute to the diabetic nephropathy as shown below  
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Histologically, the diabetic nephropathy is characterized by 
glomerular sclerosis and arterial hyalinization. Factors that determine the  
development of nephropathy are  the duration of diabetes,  severity of 
diabetes and the presence of comorbid conditions.  It has been noted that 
diabetic population with a higher level of nocturnal diastolic blood 
pressure and loss of nocturnal diastolic dipping have greater degrees of 
micro albuminuria.  Smoking and elevated blood lipid levels are also 
contributory factors for the development of  albuminuria.   Increased 
levels of mannose binding lectin have been shown to indicate the 
progression of albuminuria in diabetic patients  
Diabetic nephropathy is a leading cause of end stage renal disease 
in  both types of diabetes. Diabetic nephropathy been noted to occur in 
about 35 % of  patients who have diabetes.  Racial factors, positive 
family history , low birth weight and comorbid conditions like 
hypertension, dyslipidemia , smoking etc add to the risk of nephropathy 
in the diabetic patients. Genes responsible for diabetic nephropathy are  
assumed to be located on chromosomes 7p & 18 q. Other contributory  
factors are dietary indiscretion and elevated uric acid levels. 
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PATHOGENESIS OF DIABETIC NEPHROPATHY 
Structural alterations in the afferent vessels and glomerular 
hyperfiltration are associated with  shear stress  and  increased local 
cytokine production. Cells in the glomeruli and mesangium undergo 
proliferation due to the growth promoting effects of insulin  like growth 
factor ( IGF1),  epidermal growth factor ( EGF ), platelet derived growth 
factor, vascular endothelial growth factor (VEGF),  transforming growth ( 
TGF) and nitric oxide.  
The renal histology in diabetic nephropathy shows nodular 
glomerulosclerosis (also called Kimmelstiel Wilson lesion) and 
glomerular sclerosis. Thickening of the basement membrane occurs. 
Inflammatory cells like the monocytes,  macrophages and T Lymphocytes 
are attracted to the glomeruli by the chemotactic cytokines. Alterations  in 
the structure of the glomerular  basement membrane and reduction of the 
negatively charged heparan sulfate contribute to the increased  glomerular 
permeability. In the early stages there is selective excretion of low 
molecular weight proteins like albumin. However in later stages,  even 
high molecular weight  proteins breach the basal lamina and get excreted  
in urine. Tubulointerstitial damage is also noted in diabetic nephropathy. 
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Pro-apoptotic genes are expressed in the tubules l due to the effect 
of Angiotensin II.  Epithelial to mesenchymal transition cause conversion 
of epithelial cells to interstitial fibroblasts. These cells cause  increased 
matrix production and alteration of the basement membrane. 
Anaemia is an important contributor to diabetic nephropathy. 
Anaemia may result in renal hypoxia which induces inflammation and 
subsequent renal damage.  
Glycemic status has  been noted to correlate well  with the degree 
of diabetic nephropathy. Risk of diabetic nephropathy is low when 
HBA1c levels are less than 7 %.   
STAGES OF DIABETIC NEPHROPATHY 
Micro albuminuria is defined as the excretion of 30 to 300 
milligrams of albumin for 24 hours in at least 2 of 3 consecutive non-
ketotic sterile urine samples. Low grades of albumin excretion are  not 
detected by the routine test for protein  (example biuret test ). Instead they 
have  to be detected by dipstick method, Enzyme linked immune assays , 
nephelometry or radioimmunoassay. Spot urine samples may be used to 
detect albumin excretion. However confounding factors such as severe  
physical exertion,  urinary tract infections , non diabetic diseases of the 
kidneys  and  hematuria have to be ruled out.  
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Albuminuria more than 300 milligram per day constitutes diabetic 
nephropathy. The earliest  change of renal function in diabetes is hyper 
filtration or increase in the glomerular filtration rate. Then there is a 
gradual onset of albuminuria.  If the  patient excretes less than 30 
milligram of albumin per day , it  is known as normo-albuminuria.  
Excretion of  albumin at a rate of  30 to 300 milligrams per day is known 
as micro albuminuria. Onset of micro albuminuria accelerates the 
development of full blown diabetic nephropathy. 
Stages of diabetic nephropathy are depicted in the following picture  
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ALTERED METABOLIC PATHWAYS IN DIABETIC 
NEPHROPATHY 
PROTEIN KINASE C PATHWAY 
Elevated glucose levels have been associated with activation of the 
protein kinase C cascade, which can contribute to accumulation of the 
extracellular matrix 
ADVANCED GLYCATION END PRODUCTS 
Several advanced glycation end products have been identified in 
diabetic people. These  directly and indirectly cause  cellular hypertrophy 
and inhibition of the nitric oxide pathway. Such  changes ultimately 
produce albuminuria and sclerosis of the glomeruli. AGEs can also cause 
podocytopathy. 
POLYOL PATHWAY 
This pathway mediates the conversion of glucose to sorbitol and 
fructose.  
The enzyme aldose reductase is responsible for the conversion. 
Sorbitol can alter the extracellular matrix and basement membrane 
scaffolds.  
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PATHOGENESIS OF DIABETIC NEPHROPATHY 
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HEXOSAMINE  PATHWAY 
The hexosamine pathway converts glucose to  
N-acetylglucosamine. This  causes increased transcription of SP-1 protein 
and subsequently Transforming Growth Factor beta (TGF B) and 
Plasminogen Activator Inhibitor, which cause  renal damage 
RAAS PATHWAY 
Renin angiotensin aldosterone axis is found to be in a activated 
state in diabetic patients. Advanced glycation end products  and reactive 
oxygen species also  directly stimulate the angiotensin production.  
Angiotensinogen is converted to   Angiotensin II which results in cellular 
hypertrophy,  matrix expansion and local cytokine production all of 
which terminate in  renal damage. 
OTHER PATHWAYS 
Adenosine monophosphate activated protein kinase pathway is also 
altered in diabetic nephropathy 
Elevated uric acid can  contribute to the pre existing nephropathy 
in diabetic population  due to its  oxidative damage.  
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DIABETIC NEPHROPATHY – CORRELATION WITH 
RETINOPATHY AND CARDIO VASCULAR OUTCOME 
Diabetic nephropathy and retinopathy have a close relationship. 
Almost every patient with Type 1 Diabetes and nephropathy will have 
diabetic retinopathy. However only 50-60 %  of type 2 diabetic 
nephropathy patients will have retinopathy. 
  The onset of diabetic nephropathy can reduce the lifespan of 
diabetic patients since it heralds End stage renal disease (ESRD) as well 
as adverse cardio vascular outcomes in these patients. Urinary albumin 
excretion is an excellent predictor of the cardiovascular outcomes in 
diabetic nephropathy patients. Albuminuria is associated with endothelial 
dysfunction and accelerated atherogenesis  in such patients.  
 Hence it is mandatory to screen the fundus for retinopathic changes 
in these patients. They should also be subjected to a thorough cardio 
vascular evaluation.  Peripheral neuropathy, especially autonomic 
neuropathy is often an accompaniment to the nephropathy in these 
patient. 
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EVALUATION OF A CASE OF DIABETIC NEPHROPATHY 
 
Every diabetic nephropathy patient should be evaluated for the 
following: 
 
1. Measurement of urinary albumin and protein 
2. Measurement of serum creatinine clearance and estimation of 
glomerular  filtration  rate 
3. Management of blood pressure 
4. Ophthalmological evaluation 
5. Cardiac evaluation 
 
Micro albuminuria predicts a poor renal and cardiovascular 
outcome and hence is an indicator for targeted treatment. Overt diabetic 
nephropathy represents a stage of microalbuminuria characterized by 
daily albumin excretion of more than 300 milligram per day  
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DIFFERENTIAL DIAGNOSIS FOR DIABETIC NEPHROPATHY 
o Hematuria 
o Nephritic syndromes 
o Membranous nephropathy  
o Focal segmental glomerulosclerosis  
o Acute interstitial nephritis  
o Post infectious glomerulo nephritis 
o IgA nephropathy 
 
RENAL BIOPSY MAY BE INDICATED IN DIABETIC 
NEPHROPATHY IN THE FOLLOWING SITUATIONS 
 Sudden severe  proteinuria  
 Microscopic hematuria  
 Nephritic urinary sediment  
 Rapidly progressive renal disease  
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Approach to a case of diabetic nephropathy is as follows : 
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The other complications are 
1. Necrobiosis lipoidica diabeticorum 
2. Diabetic dermopathy 
3. Cheiro arthropathy 
4. Charcot joints 
5. Foot problems 
6. Sexual dysfunction  
7. Gastroparesis 
8. Psychological disorders like cognitive disorders, adjustment 
disorder 
9. Infectious complications 
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C REACTIVE PROTEIN 
Early stages of inflammation are  characterized by acute phase 
reactions mediated by the acute phase proteins synthesised by the liver. 
The inflammatory cytokines induce the synthesis of acute phase reactants 
One of the important acute phase reactants is C reactive protein. It 
is a very good indicator of the severity of inflammation.  It is called a C- 
reactive protein because it was noted to bind avidly to the capsular 
polysaccharide of bacterial cell wall. 
STRUCTURE OF C REACTIVE PROTEIN 
It is a pentaxin  family molecule. It is composed of  five  
polypeptide subunits. Each of the subunits contain about 200  amino acid 
residues. They have a cyclical pentameric  structure as shown below  
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EFFECTS OF CREACTIVE PROTEIN 
The predominant site of synthesis of CRP is the liver. The usual 
level is about 0.1mg% . However inflammatory states can cause several 
fold elevation of CRP. It is noted to be elevated on the third day of 
inflammation and its falls to near normal levels within about 24 hours 
after the inflammation subsides. But it should also be kept in mind that 
CRP levels may be altered by diet, smoking, hypertension, increased 
BMI, poor sleep, alcoholism etc. 
Usual conditions associated with high CRP are those that are 
associated with chronic inflammation namely rheumatoid arthritis, 
tuberculosis and neoplasms. Higher CRP levels have also been noted to 
be associated with certain chronic conditions like coronary artery disease, 
diabetes mellitus and hypertension. Value more than 10 to 12 mg%  of 
serum CRP is considered to indicate a severe inflammation. 
The physiological role of CRP is not known. However it is 
presumed that, CRP binds to the phosphoproteins, fibronectin, 
and histones which enter the circulation during the cellular apoptosis and 
CRP may facilitate their elimination. CRP can act as a bridge between 
innate and acquired immunity. It can bind to the constant position of 
antibodies and thereby activate the classical complement pathway. 
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Following pictures shows the function of CRP 
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CRP can also activate the complement pathway due to its 
interaction with C1q and C3 molecules. It can activate the membrane 
attack complex  and it activates the alternate complement cascade through 
binding with factor H. CRP can directly  induce a cytokine 
cascade, which can contribute to the inflammatory tissue damage. 
 
CRP does is used as a valuable indicator of inflammation due to 
the following factors 
(a)  It Rises early with inflammation  
(b)  The degree of rise is proportional to the severity of inflammation. 
(c)  CRP may not vary significantly with age and sex 
(d)  CRP estimation is  standardized and lab to lab variations are  
  minimal. 
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FIBRINOGEN 
Fibrinogen is a soluble plasma protein that helps in the coagulation 
pathway. It is synthesised by the liver and released into the circulation. 
Whenever the  blood vessel or endothelium is damaged, a platelet plug is 
formed and then clotting factors are activated.  All these processes 
culminate in the conversion of fibrinogen to fibrin. Fibrin forms the clot 
which secures hemostasis. The normal value is 150 to 400 mg / dl. Since 
it is an acute phase reactant it is likely to be elevated in inflammatory and 
acute stressful states.  
 Conditions associated with elevation of fibrinogen are as follows : 
1. Severe inflammation 
2. Tissue damage 
3. Sepsis 
4. Malignancy 
5. Acute coronary events 
6. Stroke 
7. Rheumatoid arthritis 
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Studies have shown that diabetic nephropathy is a pro 
inflammatory state and hence serum fibrinogen which is an acute phase 
reactant is elevated. The degree of elevation of serum fibrinogen is noted 
to correlate with  the severity of nephropathy 
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C-REACTIVE PROTEIN & SERUM FIBRINOGEN IN  
DIABETIC NEPHROPATHY 
C-reactive protein, an inflammatory marker has an excellent 
correlation with adverse cardiovascular outcomes.  CRP levels are noted 
to be increased in people with diabetes, especially so in those with 
diabetic nephropathy. It is proposed that diabetes may be associated with 
a long term immune system activation and chronic inflammatory state. 
Hence acute phase reactants namely C reactive protein,  serum amyloid 
protein,  interleukins and fibrinogen are all noted to be elevated in the 
diabetic population. The advanced glycation end products may alter the  
intracellular signalling and gene expression as a result of which the 
inflammatory responses become altered.  A pro inflammatory state 
ensues, with associated elevation of acute phase.  
  
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
Aims and Objectives 
To study the co-relation between levels of acute phase reactants ( 
serum CRP , serum fibrinogen ) and severity of albuminuria in patients 
admitted with type 2 diabetes mellitus. 
 
Study center 
Institute of Internal Medicine, Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai 
 
Duration  of study  
6 months 
 
Study design 
Observational Study 
 
Sample size 
100  patients 
 
Inclusion criteria 
1. Patients with Type 2 Diabetes mellitus  (less than 10 years of           
duration) attending the  OPD 
2. Age : less than 50 years 
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Exclusion criteria 
 Patients with current or recent (< 1 week ) infectious diseases  
(UTI,LRI , sepsis , AGE , viral fever  etc )  
 Patients with cancer 
 Patients with uncontrolled hypertension ( > 160/90 ) 
 Smokers 
  Known cases of immunological disorders 
 Patients with clinical history of cardiovascular diseases 
 Pregnancy 
 Patients with known history of CVA , CAD 
 Known cases of CKD 
 
Data collection and methods  
Patients are subjected to detailed history taking and clinical 
examination. 
 
Materials and methods 
100 Patients with type 2 diabetes mellitus, attending the OPD  are 
selected for clinical study as per inclusion / exclusion criteria and are 
subjected to clinical assessment ( BMI, Waist hip ratio, blood pressure) 
and laboratory evaluation (serum  CRP, serum fibrinogen, serum 
creatinine , fasting plasma glucose , 24 hours urinary albumin excretion ). 
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Routine investigations (complete blood counts, urine routine, 
electrocardiogram, chest X ray, ultrasound abdomen)  are also done. 
 
Procedure / Investigation Details 
1. Serum Creatinine   :  Calorimetric method 
2. Plasma fasting glucose  :  Automated enzyme method 
3. 24 hrs urine albumin   :  Turbidimetry 
4. Serum CRP    :  Immuno assay 
5. Serum fibrinogen   :  Automated enzyme method 
 
Analysis plan 
SPSS - epi info software 
 
Sponsorship  
No  
 
Conflict of interest 
None 
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65 
 
OBSERVATIONS AND RESULTS 
AGE DISTRIBUTION OF THE PATIENTS IN THE STUDY 
 
 
 
A total of 100 patients were included in the study. 
The age groups < 35 years, 36-40 years, 41-45 years and 46-50 
years contained 5, 16, 43 and 36 numbers of patients respectively 
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GENDER WISE DISTRIBUTION OF THE PATIENTS  
IN THE STUDY 
 
 
The study included 42 males and 48 females. 
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COMPARISON OF MULTIPLE  PARAMETERS BETWEEN 
NORMO ALBUMINURIC GROUP AND MICRO/OVERT 
ALBUMINURIC GROUP 
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This table shows that systolic BP did not correlate with degree of 
albuminuria (p value =0.092 ) , but the diastolic BP shows a good 
correlation with severity of albuminuria ( p value =0.001) 
A higher BMI was noted to be associated with a higher degree of 
albuminuria ( p value =0.001) 
Fasting blood sugar did not show a correlation with albuminuria   
( p value =0.06) 
HBA1C correlates with excretion of albumin as shown by the  p 
value of 0.001 
Higher albumin excretion rates are associated with higher levels of 
CRP ( p value =0.031) 
Higher albumin excretion rates are associated with higher levels of 
Sr.Fibrinogen  (p value =0.001) 
Albuminuria grade correlates with serum creatinine values   
(p value = 0.001) 
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ALBUMINURIA CLASSES IN THE STUDY 
 
The following table shows the correlation between sex and grades 
of albuminuria 
 
Urine_ACR_class * SEX Cross tabulation 
Urine_acr_class 
SEX 
Total 
Male Female 
<30 Normal 
Count 17 13 30 
% within Urine_acr_class 56.7% 43.3% 100.0% 
30-300 MICRO 
ALBUMINURIA 
Count 24 17 41 
% within Urine_acr_class 58.5% 41.5% 100.0% 
>300 MACRO 
ALBUMINURIA 
Count 17 12 29 
% within Urine_acr_class 58.6% 41.4% 100.0% 
Total 
Count 58 42 100 
% within Urine_acr_class 58.0% 42.0% 100.0% 
 
 
  
 
 
 
In our study, 30 patients belonged to the normo albuminuric group 
while 41 belonged to the micro albuminuric group and 29 belonged to the 
macro albuminuric 
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CORRELATION BETWEEN GRADE OF ALBUMINURIA 
AND LEVELS OF C-REACTIVE PROTEIN 
The following table shows the correlation  between grade of 
albuminuria and levels of c-reactive protein 
Chi-Square=22.019* p<0.001 
  
Crosstab 
Urine_acr_class 
CRP_CLASS 
Total NORMAL 
UPTO 10 
ABNORMA
L ABOVE 
10 
<30 Normal 
Count 22 8 30 
% within 
Urine_acr_class 
73.3% 26.7% 100.0% 
30-300 MICRO 
ALBUMINURIA 
Count 29 12 41 
% within 
Urine_acr_class 
70.7% 29.3% 100.0% 
>300 MACRO 
ALBUMINURIA 
Count 6 23 29 
% within 
Urine_acr_class 
20.7% 79.3% 100.0% 
Total 
Count 57 43 100 
% within 
Urine_acr_class 
57.0% 43.0% 100.0% 
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This chart indicates that micro albuminuria and macro albuminuria 
are associated with higher levels of CRP  when compared to  the normo 
albuminuric patients. 
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CORRELATION BETWEEN GRADE OF ALBUMINURIA 
AND LEVELS OF SERUM FIBRINOGEN 
Urine_acr_class * FIBRINOGEN Crosstabulation 
Urine_acr_class 
FIBRINOGEN 
Total NORMAL 
UPTO 350 
ABNORMAL 
ABOVE 350 
<30 Normal 
Count 29 1 30 
% within 
Urine_acr_class 
96.7% 3.3% 100.0% 
30-300 MICRO 
ALBUMINURIA 
Count 39 2 41 
% within 
Urine_acr_class 
95.1% 4.9% 100.0% 
>300 MACRO 
ALBUMINURIA 
Count 7 22 29 
% within 
Urine_acr_class 
24.1% 75.9% 100.0% 
Total 
Count 75 25 100 
% within 
Urine_acr_class 
75.0% 25.0% 100.0% 
 
 
  
This table illustrates that serum fibrinogen is elevated in overt and 
macro albuminuric groups than normo albuminuric group.
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CORRELATION BETWEEN GRADE OF ALBUMINURIA 
AND SERUM CREATININE 
 
Crosstab 
Urine_acr_class 
SERUM_CREATININE 
Total NORMAL 
UPTO 1.2 
ABNORMA
L ABOVE 
1.2 
<30 Normal 
Count 28 2 30 
% within Urine_acr_class 93.3% 6.7% 100.0% 
30-300 MICRO 
ALBUMINURIA 
Count 29 12 41 
% within Urine_acr_class 70.7% 29.3% 100.0% 
>300 MACRO 
ALBUMINURIA 
Count 7 22 29 
% within Urine_acr_class 24.1% 75.9% 100.0% 
Total 
Count 64 36 100 
% within Urine_acr_class 64.0% 36.0% 100.0% 
Chi-Square=32.010* p<0.001 
 
  
 
The above picture shows that higher levels of albumin excretion 
correspond to higher levels of serum creatinine. Thus albumin excretion 
in the urine is a good indicator of the glomerular filtration. 
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CORRELATION BETWEEN GRADE OF 
ALBUMINURIA AND BLOOD PRESSURE 
Crosstab 
Urine_acr_class 
BLOOD_PRESSURE 
Total UPTO 120/80 ABOVE 
120/80 
<30 Normal 
Count 13 17 30 
% within 
Urine_acr_class 
43.3% 56.7% 100.0% 
30-300 MICRO 
ALBUMINURIA 
Count 22 19 41 
% within 
Urine_acr_class 
53.7% 46.3% 100.0% 
>300 MACRO 
ALBUMINURIA 
Count 3 26 29 
% within 
Urine_acr_class 
10.3% 89.7% 100.0% 
Total 
Count 38 62 100 
% within 
Urine_acr_class 
38.0% 62.0% 100.0% 
 
 
  
The above graph shows that higher blood pressures in diabetics are 
associated with greater 
contributor to the diabetic nephropathy. A direct comparison by means of 
Chi square indicated that diastolic bp correlates well with albuminuria , 
but systolic bp does not correlate to it.
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CORRELATION BETWEEN GRADE OF 
ALBUMINURIA ANDBODY MASS INDEX 
 
 
Crosstab 
Urine_acr_class 
BMI_CLASS 
Total 18.5-22.9 
NORMAL 
23-24.9 
OVERWEIGHT 
25-29.9 
PRE 
OBESE 
ABOVE 
29.9 
OBESE 
<30 Normal 
Count 12 13 4 1 30 
% within 
Urine_acr_class 
40.0% 43.3% 13.3% 3.3% 100.0% 
30-300 MICRO 
ALBUMINURIA 
Count 19 12 10 0 41 
% within 
Urine_acr_class 
46.3% 29.3% 24.4% 0.0% 100.0% 
>300 MACRO 
ALBUMINURIA 
Count 4 2 11 12 29 
% within 
Urine_acr_class 
13.8% 6.9% 37.9% 41.4% 100.0% 
Total 
Count 35 27 25 13 100 
% within 
Urine_acr_class 
35.0% 27.0% 25.0% 13.0% 100.0% 
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This chart shows that a higher body mass index is associated with 
greater degrees of diabetic nephropathy. Thus obese patients are more 
prone to develop renal complications of diabetes. 
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CORRELATION BETWEEN GRADE OF 
ALBUMINURIA AND DURATION OF DIABETES 
Crosstab 
Urine_acr_class 
DURATION_dm 
Total 1-3 
YEARS 
4-6 
YEARS 
ABOVE 7 
YEARS 
<30 Normal 
Count 24 5 1 30 
% within 
Urine_acr_class 
80.0% 16.7% 3.3% 100.0% 
30-300 MICRO 
ALBUMINURIA 
Count 34 7 0 41 
% within 
Urine_acr_class 
82.9% 17.1% 0.0% 100.0% 
>300 MACRO 
ALBUMINURIA 
Count 8 11 10 29 
% within 
Urine_acr_class 
27.6% 37.9% 34.5% 100.0% 
Total 
Count 66 23 11 100 
% within 
Urine_acr_class 
66.0% 23.0% 11.0% 100.0% 
Chi-Square=33.766* p<0.001 
 
 
 
  
The study included only people below 50 years of age , since age 
itself is a confounding factor for the two variables 
Despite this limitation, the study shows that greater duration
diabetes is associated with greater degrees of albuminuria.
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As already mentioned , the study inclusion criteria of only diabetic 
patients < 50 years 
albuminuria. But still the above chart illustrates that micro and overt 
albuminuria are more likely in higher age groups.
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– limits an accurate comparison of age with 
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CORRELATION BETWEEN GRADE OF 
ALBUMINURIA AND LEVELS OF HBA1C 
Crosstab 
Urine_acr_class 
hba1c_class 
Total <6.5 
Normal 
>6.5 
Abnormal 
<30 Normal 
Count 25 5 30 
% within 
Urine_acr_class 
83.3% 16.7% 100.0% 
30-300 MICRO 
ALBUMINURIA 
Count 30 11 41 
% within 
Urine_acr_class 
73.2% 26.8% 100.0% 
>300 MACRO 
ALBUMINURIA 
Count 5 24 29 
% within 
Urine_acr_class 
17.2% 82.8% 100.0% 
Total 
Count 60 40 100 
% within 
Urine_acr_class 
60.0% 40.0% 100.0% 
Chi-Square=31.861* p<0.001 
 
  
 
The micro and macro albuminuric groups are noted to have higher 
HBA1C levels than the normoalbuminuric group, implying that a tighter 
glycemic control can reduce
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DISCUSSION 
The study included 100 diabetic patients without other known 
comorbids and aged less than 50 years. These patients were subjected to 
several laboratory investigations namely HBA1C, fasting blood sugar, 
serum creatinine, serum fibrinogen, serum CRP, urine albumin creatinine 
ratio and physical findings like BMI, blood pressure were recorded. 
Several previous investigators have proposed that diabetes is in 
itself an inflammatory state and that the grade of diabetic nephropathy 
corresponds to the severity of the inflammation.  
Joydeep Gosh, Mrinal Pal et al  showed that serum sialic acid, an 
inflammatory marker is elevated in diabetics , especially so in diabetic 
nephropathy cases. The extent of elevation corresponds to the degree of 
proteinuria. This suggests that diabetes and diabetic nephropathy are 
inflammatory states. 
Sumesh Raj, G.V.Rajan et al showed a similar relationship 
between the degree of albuminuria and levels of serum ferritin. 
 Similar studies were conducted  with other major acute phase 
reactants. Vishakha V,  Mahajan et al., conducted a study in three major 
acute phase reactants - serum CRP, serum ceruloplasmin and  serum 
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sialic acid. They demonstrated a positive correlation between the levels of 
these acute phase reactants and the complications of diabetes especially 
diabetic nephropathy. 
Tan K.C. et al., showed that in diabetes , there is  production of 
advanced end glycation products by non enzymatic reaction which is 
responsible for a pro-inflammatory state.  The inflammation may have a 
role in the development of the proteinuria. 
Michele Dalla Vestra et al showed a significant correlation 
between the elevated levels of serum fibrinogen, serum CRP, IL 6, SAA 
and grade of proteinuria. This study revealed that the elevated fibrinogen 
causes glomerular matrix thickening via inflammatory pathways. This 
GBM thickening leads to protenuria. This study concluded that low grade 
inflammation is causes nephropathy by causing basement membrane 
alterations. 
The Casale Monferrato study showed that fibrinogen is a single 
independent marker  to assess the progression diabetic nephropathy. 
Chaudhary et al study explained the 3 major mechanisms of 
progression of albuminuria and its correlation with acute phase reactant. 
They proposed that elevated levels of acute phase reactants  directly 
injure the glomeruli and thereby alter their function 
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In our study there is a positive correlation between the levels of 
CRP- fibrinogen and the severity of albuminuria (measured by urine 
albumin excretion ratio). This suggests that diabetes itself is a chronic 
inflammatory state and this  inflammatory damage may be responsible for 
some of the diabetic complications, especially diabetic nephropathy. 
Other parameters were also correlated to the grade of albuminuria 
in the study. Results show that a higher diastolic BP correlates well with a 
higher degree of albuminuria, but systolic BP did not have a correlation 
with albuminuria. A study by Azeem Taj et al came up with similar 
results. It showed that  diabetics with a higher blood pressure were more 
likely to have nephropathy. 
Our study also showed that greater BMI levels are associated with 
higher urinary albumin excretion. Likewise, higher HBA1C levels and 
greater duration of diabetes were noted to correlate to  higher grades of 
albuminuria. Similar results had been obtained by M.Afkhami et al. 
However fasting sugar level did not have a significant association with 
albuminuria in our study. 
  
CONCLUSION 
 
 
 
 
 
89 
 
CONCLUSION 
Diabetics with a higher blood pressure are more likely to develop 
nephropathy than the normotensive diabetic people. 
A higher body mass index is associated with higher grade of 
albuminuria. In other words, obese diabetic patients are more prone for 
developing nephropathy than others. 
Higher HBA1C and longer duration of diabetes can lead to more 
severe nephropathy. Thus a poor glycemic control predicts greater 
degrees of nephropathy 
Acute phase reactants namely serum CRP and serum fibrinogen are 
elevated in diabetic nephropathy , suggesting that it is an inflammatory 
state. Hence serum CRP and fibrinogen may be used as predictors of 
nephropathy in diabetic patients.  
  
LIMITATIONS 
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LIMITATIONS OF THE STUDY 
• The study has included only diabetic nephropathy and has not  
assessed the other major complications of diabetes. 
• Sample size is moderate 
• Effects of the anti diabetic medications have not been included in 
the assessment. 
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ANNEXURES 
 
  
  
PROFORMA 
 
 
Name:      Age/Sex: 
 
Address:      Occupation: 
 
Duration of  Diabetes : 
 
 
 
i. Blood pressure 
 
ii. Height 
 
iii. Weight 
 
iv. Body mass index 
 
v. Waist hip ratio 
 
 
Systemic examination  
 
CVS 
 
RS 
 
ABDOMEN 
 
CNS 
INVESTIGATIONS 
 
 COMPLETE HEMOGRAM 
 
 
 
  
 
 
 URINE ROUTINE   : 
 
 
 URINE ACR    : 
 
 
 SERUM CREATININE   : 
 
 
 24 HOURS URINE ALBUMIN : 
 
 
 SERUM CRP    : 
 
 
 SERUM FIBRINOGEN   : 
 
 
 FASTING PLASMA SUGAR  : 
 
 
 ELECTROCARDIOGRAM  : 
 
 
 CHEST X-RAY     : 
 
 
 ULTRASOUND ABDOMEN  : 
  
  
  
  
 
 
 
  
  
  
INFORMATION SHEET 
 
We are conducting a study - “A STUDY OF CO-RELATION  
BETWEEN LEVELS OF ACUTE PHASE REACTANTS ( SERUM 
CRP, SERUM FIBRINOGEN) AND SEVERITY OF 
ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES 
MELLITUS ” among patients attending Rajiv Gandhi Government 
General Hospital, Chennai and for that your specimen may be valuable to 
us. 
 
The purpose of this study is to compare the levels of  acute phase 
reactants namely serum CRP and serum Fibrinogen with the levels of 
albuminuria  in patients with type 2 diabetes . 
 
We are selecting certain cases and if you are found eligible, we 
may be using your blood samples to do certain tests which in any way do 
not affect your final report or management. 
 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
 
Signature of Participant     Signature of Investigator 
 
Date: 
Place: 
  
  
  
PATIENT CONSENT FORM 
Study Detail : “A STUDY OF CO-RELATION  BETWEEN LEVELS 
OF ACUTE PHASE REACTANTS ( SERUM CRP, 
SERUM FIBRINOGEN ) AND SEVERITY OF 
ALBUMINURIA IN PATIENTS WITH TYPE 2 
DIABETES MELLITUS” 
 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. 
I have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction. ❏ 
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
c) I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study. ❏ 
d) I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and blood 
investigations as required. ❏ 
 
Signature of Investigator    Signature of Participant 
 
 
Patient’s Name and Address     
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 KEY TO MASTER CHART 
 
S.NO   -  SERIAL NUMBER 
DM      - DIABETES MELLITUS 
FBS     - FASTING BLOOD SUGAR 
HBA1C   - GLYCOSYLATED HEMOGLOBIN 
CRP    - C-REACTIVE PROTEIN 
ACR    - ALBUMIN CREATINIE RATIO 
BMI    - BODY MASS INDEX 
 
